• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early treatment of rheumatoid arthritis: rationale, evidence, and implications.

作者信息

van de Putte L B, van Gestel A M, van Riel P L

机构信息

Department of Rheumatology, University Hospital Nijmegen, The Netherlands.

出版信息

Ann Rheum Dis. 1998 Sep;57(9):511-2. doi: 10.1136/ard.57.9.511.

DOI:10.1136/ard.57.9.511
PMID:9849307
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1752733/
Abstract
摘要

相似文献

1
Early treatment of rheumatoid arthritis: rationale, evidence, and implications.类风湿关节炎的早期治疗：理论依据、证据及影响
Ann Rheum Dis. 1998 Sep;57(9):511-2. doi: 10.1136/ard.57.9.511.
2
[Levamisole used in rheumatoid arthritis].[左旋咪唑用于类风湿性关节炎]。
Acta Rhumatol. 1979 Jul-Sep;3(3):219-30.
3
Acute inflammatory arthritis: are glucocorticoids of benefit in very early arthritis?
Nat Rev Rheumatol. 2010 Apr;6(4):185-6. doi: 10.1038/nrrheum.2010.39.
4
Should aggressive therapy for rheumatoid arthritis require early use of weekly low-dose methotrexate, as the first disease-modifying anti-rheumatic drug in most patients?
Rheumatology (Oxford). 2006 May;45(5):497-9. doi: 10.1093/rheumatology/kel014. Epub 2006 Mar 14.
5
Early therapy is nothing new in rheumatoid arthritis.
Rheumatology (Oxford). 2000 Dec;39(12):1439. doi: 10.1093/rheumatology/39.12.1439.
6
Rheumatoid arthritis: the goal rather than the health-care provider is key.类风湿关节炎：目标而非医疗服务提供者才是关键。
Lancet. 2006 Feb 11;367(9509):450-2. doi: 10.1016/S0140-6736(06)68154-3.
7
Advances in the treatment of early rheumatoid arthritis.早期类风湿关节炎的治疗进展
Am Fam Physician. 2005 Sep 15;72(6):1002, 1004.
8
The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials.类风湿关节炎中生物制剂撤药的时机和方法：从大型随机对照试验中学习。
Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S19-21. Epub 2013 Oct 3.
9
Should rheumatoid arthritis be treated conservatively or aggressively?
Rheumatology (Oxford). 2003 May;42 Suppl 2:ii41-3. doi: 10.1093/rheumatology/keg332.
10
Methotrexate use in rheumatoid arthritis.甲氨蝶呤在类风湿关节炎中的应用。
Rheum Dis Clin North Am. 1997 Nov;23(4):779-96. doi: 10.1016/s0889-857x(05)70360-4.

引用本文的文献

1
Association of Hematological and Biochemical Parameters and HLA-DRB1 Alleles With Anti-cyclic Citrullinated Peptide Autoantibodies in Sudanese Rheumatic Patients.苏丹风湿性疾病患者血液学和生化参数及HLA - DRB1等位基因与抗环瓜氨酸肽自身抗体的关联
Cureus. 2024 Apr 18;16(4):e58551. doi: 10.7759/cureus.58551. eCollection 2024 Apr.
2
Erosion-free rheumatoid arthritis: clinical and conceptional implications-a BARFOT study.无糜烂性类风湿关节炎：临床及概念意义——一项BARFOT研究
BMC Rheumatol. 2022 Dec 30;6(1):88. doi: 10.1186/s41927-022-00317-4.
3
A Study on Association between Common Haematological Parameters and Disease Activity in Rheumatoid Arthritis.类风湿关节炎常见血液学参数与疾病活动度的相关性研究
J Clin Diagn Res. 2017 Jan;11(1):EC01-EC04. doi: 10.7860/JCDR/2017/23524.9130. Epub 2017 Jan 1.
4
The Relationship of Cytokines IL-13 and IL-17 with Autoantibodies Profile in Early Rheumatoid Arthritis.细胞因子IL-13和IL-17与早期类风湿关节炎自身抗体谱的关系
J Immunol Res. 2016;2016:3109135. doi: 10.1155/2016/3109135. Epub 2016 Aug 4.
5
Comparing Five Year Out-Come in Two Cohorts of Patients with Early Rheumatoid Arthritis - A BARFOT Study.比较两组早期类风湿关节炎患者的五年预后——一项BARFOT研究
Open Rheumatol J. 2015 Feb 3;9:8-15. doi: 10.2174/1874312901409010008. eCollection 2015.
6
Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis.早期类风湿关节炎患者四个队列的治疗策略、疾病活动度及预后
Ann Rheum Dis. 2001 May;60(5):453-8. doi: 10.1136/ard.60.5.453.
7
No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset.类风湿关节炎患者死亡率未增加：自疾病发作起长达10年的随访
Ann Rheum Dis. 2000 Dec;59(12):954-8. doi: 10.1136/ard.59.12.954.

本文引用的文献

1
Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study.金诺芬可改善早期类风湿性关节炎的预后。一项为期两年的双盲安慰剂对照研究结果。
J Rheumatol. 1988 Dec;15(12):1747-54.
2
Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs).使用慢作用抗风湿药物（SAARDs）治疗早期类风湿关节炎患者。
Baillieres Clin Rheumatol. 1997 Feb;11(1):65-82. doi: 10.1016/s0950-3579(97)80033-7.
3
Biologic agents for treating rheumatoid arthritis. Concepts and progress.治疗类风湿关节炎的生物制剂。概念与进展。
Arthritis Rheum. 1997 Mar;40(3):397-409. doi: 10.1002/art.1780400302.
4
Natural remission in inflammatory polyarthritis: issues of definition and prediction.炎性多关节炎的自然缓解：定义与预测问题
Br J Rheumatol. 1996 Nov;35(11):1096-100. doi: 10.1093/rheumatology/35.11.1096.
5
Biologic agents for the treatment of rheumatoid arthritis.用于治疗类风湿性关节炎的生物制剂。
Rheum Dis Clin North Am. 1996 Feb;22(1):117-32. doi: 10.1016/s0889-857x(05)70265-9.
6
A perspective on anti-cytokine and anti-T cell-directed therapies in rheumatoid arthritis.类风湿关节炎中抗细胞因子和抗T细胞导向疗法的展望
Clin Exp Rheumatol. 1995 Sep-Oct;13 Suppl 12:S35-40.
7
Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study.类风湿关节炎患者从早期二线治疗中获益：一项前瞻性双盲安慰剂对照研究的5年随访
J Rheumatol. 1995 Dec;22(12):2208-13.
8
Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy.采用“锯齿”策略治疗的早期类风湿关节炎患者的结局
Arthritis Rheum. 1996 Jun;39(6):996-1005. doi: 10.1002/art.1780390617.
9
Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra.抗细胞因子治疗DBA/1小鼠已建立的II型胶原诱导性关节炎。使用抗TNFα、抗IL-1α/β和IL-1Ra的比较研究。
Arthritis Rheum. 1996 May;39(5):797-809. doi: 10.1002/art.1780390513.
10
The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.“二线”抗风湿药物早期治疗的有效性。一项随机对照试验。
Ann Intern Med. 1996 Apr 15;124(8):699-707. doi: 10.7326/0003-4819-124-8-199604150-00001.